Key result
Thoracoscopic epicardial ablation with a bi-atrial lesion set reduced atrial tachyarrhythmia recurrence compared to a box lesion set (HR 0.447; 95% CI 0.208-0.963; P=0.040).
Why the study?
Thoracoscopic epicardial ablation with limited lesions yields suboptimal results for advanced paroxysmal or persistent AF, and whether additional right atrial lesions improve outcomes is unclear.
Does thoracoscopic epicardial ablation with bi-atrial lesion sets improve freedom from atrial tachyarrhythmias in patients with paroxysmal or persistent AF and LA dilation compared to box lesions?
Cohort (n=80)
No
Does thoracoscopic epicardial ablation with bi-atrial lesion sets improve freedom from atrial tachyarrhythmias in patients with paroxysmal or persistent AF and LA dilation compared to box lesions?
Thoracoscopic epicardial ablation with bi-atrial lesion sets may provide better freedom from atrial tachyarrhythmias than box lesions for paroxysmal or persistent AF with LA dilation.
Bi-atrial lesions were associated with lower recurrence after thoracoscopic ablation; hypothesis-generating pending randomized confirmation.
OBJECTIVES: Thoracoscopic epicardial ablation with a limited lesion set led to suboptimal results for advanced paroxysmal atrial fibrillation (AF) or persistent AF. Whether additional right atrial lesions improve the result is unclear. METHODS: We conducted a retrospective study involving 80 consecutive patients with paroxysmal or persistent AF, left atrial (LA) dilation (LA diameter >40 mm) and failed prior interventional ablation (40 patients, 50%) who underwent thoracoscopic epicardial ablation with box lesions (36 patients) or bi-atrial (BA) lesion (44 patients) in our institution. Freedom from atrial tachyarrhythmias after the procedures was compared between the box lesion group and BA lesion group. RESULTS: Baseline differences included more patients with persistent AF (86.4% vs 47.2%) and larger left atrium [48.00 (44.00-50.75) vs 42.00 (41.25-44.00) mm] in the BA lesion group. There was no difference in procedural complications between the 2 groups. After a mean follow-up of 32 months, the freedom from atrial tachyarrhythmias off antiarrhythmic drugs at 6, 12 and 24 months was 77.2%, 77.2% and 77.2% in the BA lesion group and 69.4%, 50.0% and 40.6% in the box lesion group, respectively (P = 0.006). After adjustment for sex, age, body mass index, LA diameter, AF type, history of AF, and previous interventional ablation, BA lesion was an independent predictor of lower atrial tachyarrhythmia recurrence (hazard ratio 0.447, 95% confidential interval 0.208-0.963; P = 0.040). CONCLUSIONS: Compared with the box lesion set, thoracoscopic epicardial ablation with BA lesion sets might provide better freedom from atrial tachyarrhythmias for paroxysmal or persistent AF with LA dilation. Randomized control trials are warranted to confirm the benefit of BA lesion sets in these patients.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2021) conducted a cohort in Paroxysmal or persistent atrial fibrillation with left atrial dilation (n=80). Bi-atrial lesion set vs. Box lesion set was evaluated on Freedom from atrial tachyarrhythmias off antiarrhythmic drugs at 24 months (HR 0.447, 95% CI 0.208-0.963, p=0.040). Thoracoscopic epicardial ablation with a bi-atrial lesion set reduced atrial tachyarrhythmia recurrence compared to a box lesion set (HR 0.447; 95% CI 0.208-0.963; P=0.040).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: